RT Journal Article SR Electronic T1 ▼Bevacizumab and ▼cetuximab for colorectal cancer JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 37 OP 40 DO 10.1136/dtb.2006.44537 VO 44 IS 5 YR 2006 UL http://dtb.bmj.com/content/44/5/37.abstract AB Relevant BNF section: 8.1.5Every year in the UK, around 16,000 people die from colorectal cancer, the second commonest cause of death from cancer in the UK after lung cancer.1 Over half of all people with colorectal cancer eventually die of metastatic disease.2 While median survival has increased with optimal use of combination chemotherapy,3,4 only a small minority of patients are still alive 5 years after diagnosis of metastases.5 ▼Bevacizumab (pronounced be-va-see-zoo-mab) (Avastin - Roche) and ▼cetuximab (se-tuks-ee-mab) (Erbitux - Merck) are two new monoclonal antibodies licensed for treating patients with metastatic colorectal cancer. Here we assess their efficacy and safety.